168 related articles for article (PubMed ID: 20628518)
1. Aldo-keto reductases in the eye.
Huang SP; Palla S; Ruzycki P; Varma RA; Harter T; Reddy GB; Petrash JM
J Ophthalmol; 2010; 2010():521204. PubMed ID: 20628518
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
[TBL] [Abstract][Full Text] [Related]
3. AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer.
Hojnik M; Šuster NK; Smrkolj Š; Sisinger D; Grazio SF; Verdenik I; Rižner TL
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159076
[TBL] [Abstract][Full Text] [Related]
4. Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives.
Liu J; Wen G; Cao D
Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):246-53. PubMed ID: 19522700
[TBL] [Abstract][Full Text] [Related]
5. AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas.
Hojnik M; Frković Grazio S; Verdenik I; Rižner TL
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298614
[TBL] [Abstract][Full Text] [Related]
6. Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer.
Taskoparan B; Seza EG; Demirkol S; Tuncer S; Stefek M; Gure AO; Banerjee S
Cell Oncol (Dordr); 2017 Dec; 40(6):563-578. PubMed ID: 28929377
[TBL] [Abstract][Full Text] [Related]
7. AKR1B10 is induced by hyperglycaemia and lipopolysaccharide in patients with diabetic nephropathy.
Shaw N; Yang B; Millward A; Demaine A; Hodgkinson A
Cell Stress Chaperones; 2014 Mar; 19(2):281-7. PubMed ID: 23975544
[TBL] [Abstract][Full Text] [Related]
8. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Takemura M; Endo S; Matsunaga T; Soda M; Zhao HT; El-Kabbani O; Tajima K; Iinuma M; Hara A
J Nat Prod; 2011 May; 74(5):1201-6. PubMed ID: 21561086
[TBL] [Abstract][Full Text] [Related]
10. Engineering aldo-keto reductase 1B10 to mimic the distinct 1B15 topology and specificity towards inhibitors and substrates, including retinoids and steroids.
Giménez-Dejoz J; Weber S; Fernández-Pardo Á; Möller G; Adamski J; Porté S; Parés X; Farrés J
Chem Biol Interact; 2019 Jul; 307():186-194. PubMed ID: 31028727
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Analysis of mRNA and Protein Expression Levels of Aldo-Keto Reductase and Short-Chain Dehydrogenase/Reductase Isoforms in the Human Intestine.
Hirosawa K; Fujioka H; Morinaga G; Fukami T; Ishiguro N; Kishimoto W; Nakase H; Mizuguchi H; Nakajima M
Drug Metab Dispos; 2023 Dec; 51(12):1569-1577. PubMed ID: 37722844
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Ebert B; Kisiela M; Wsól V; Maser E
Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737
[TBL] [Abstract][Full Text] [Related]
13. Selective Inhibition of Human AKR1B10 by
Seliger JM; Cicek SS; Witt LT; Martin HJ; Maser E; Hintzpeter J
Molecules; 2018 Nov; 23(11):. PubMed ID: 30469331
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Phenylcarbamoylazinane-1,2,4-Triazole Amides Derivatives as the Potential Inhibitors of Aldo-Keto Reductases (AKR1B1 & AKRB10): Potential Lead Molecules for Treatment of Colon Cancer.
Saeed A; Ejaz SA; Sarfraz M; Tamam N; Siddique F; Riaz N; Qais FA; Chtita S; Iqbal J
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807227
[TBL] [Abstract][Full Text] [Related]
15. Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers.
Laffin B; Petrash JM
Front Pharmacol; 2012; 3():104. PubMed ID: 22685431
[TBL] [Abstract][Full Text] [Related]
16. Human and rodent aldo-keto reductases from the AKR1B subfamily and their specificity with retinaldehyde.
Ruiz FX; Moro A; Gallego O; Ardèvol A; Rovira C; Petrash JM; Parés X; Farrés J
Chem Biol Interact; 2011 May; 191(1-3):199-205. PubMed ID: 21329680
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
Gallego O; Ruiz FX; Ardèvol A; Domínguez M; Alvarez R; de Lera AR; Rovira C; Farrés J; Fita I; Parés X
Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20764-9. PubMed ID: 18087047
[TBL] [Abstract][Full Text] [Related]
18. Overexpression and enhanced specific activity of aldoketo reductases (AKR1B1 & AKR1B10) in human breast cancers.
Reddy KA; Kumar PU; Srinivasulu M; Triveni B; Sharada K; Ismail A; Reddy GB
Breast; 2017 Feb; 31():137-143. PubMed ID: 27855345
[TBL] [Abstract][Full Text] [Related]
19. Aldo Keto Reductases AKR1B1 and AKR1B10 in Cancer: Molecular Mechanisms and Signaling Networks.
Banerjee S
Adv Exp Med Biol; 2021; 1347():65-82. PubMed ID: 33945128
[TBL] [Abstract][Full Text] [Related]
20. Role of human aldo-keto-reductase AKR1B10 in the protection against toxic aldehydes.
Martin HJ; Maser E
Chem Biol Interact; 2009 Mar; 178(1-3):145-50. PubMed ID: 19013440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]